SARASOTA, Fla. and INDIANAPOLIS — December 1, 2025 — Leads & Copy — INVO Fertility, Inc. (Nasdaq: IVF) has announced its intent to acquire Family Beginnings, P.C., an Indiana-based fertility clinic serving patients across the Midwest.
The planned acquisition marks INVO’s second after its purchase of Wisconsin Fertility Institute in 2023 and reflects the company’s strategic initiative to build a nationwide network of fertility centers.
Steve Shum, CEO of INVO, said Family Beginnings has long been recognized for its exceptional standards of care, and he welcomed Dr. James Donahue and his team to INVO. He said the two share a common philosophy centered on compassionate, patient-first treatment.
Shum added that Dr. Donahue was an early adopter and remains a strong advocate of INVO’s innovative INVOcell technology. He said the intravaginal culture (IVC) solution is well integrated into Donahue’s practice and is one of several treatment options offered to patients.
Founded in the late 1990s, Family Beginnings has served thousands of patients across Indiana and surrounding states and is known for its personalized care model and strong success rates. The clinic offers a full suite of reproductive services, including in vitro fertilization (IVF), INVOcell (IVC), intrauterine insemination (IUI), third-party reproduction services, fertility preservation, advanced diagnostic testing, and comprehensive patient education and support programs.
James Donahue M.D., HCLD and founder of Family Beginnings, said the two teams share a deep commitment to helping individuals and families achieve their dreams of parenthood. He added that by partnering with INVO, Family Beginnings will be able to broaden its offerings, introduce new and innovative treatment options, and ensure that even more patients benefit from the high level of care it has always provided.
With this acquisition, INVO plans to enhance the Family Beginnings clinic by introducing expanded treatment options; investing in clinic infrastructure and technology to improve workflow efficiencies; integrating digital patient engagement tools for streamlined communication and care coordination; and leveraging INVO’s national network to provide patients with broader access to resources, support programs, and clinical expertise.
Shum said the acquisition is a natural fit with INVO’s mission to make fertility care more accessible and patient-centered and that acquisitions like this are a core component of its growth plan. INVO executed a term sheet with Dr. Donahue over a month ago and expects to close the transaction in the near-term.
The acquisition remains subject to completion of customary due diligence by INVO and the negotiation and entry into definitive purchase agreements between INVO and Family Beginnings, including customary covenants, closing conditions, any required regulatory approvals, indemnification provisions and termination rights. There can be no assurances that INVO will enter into a definitive agreement or complete the acquisition.
About INVO Fertility
INVO Fertility is a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (ART) care to patients. Its principal commercial strategy focuses on building, acquiring, and operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell® medical device and US-based, profitable in vitro fertilization (IVF) clinics. INVO has two operational INVO Centers in the United States and one IVF clinic. The company also continues to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. INVO believes the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination.
Steve Shum, CEO, 978-878-9505, sshum@invofertility.com
Robert Blum, Lytham Partners, LLC, 602-889-9700, INVO@lythampartners.com
